Dharam Kumbhani, MD
Interventional Cardiology · Dallas, TXNPI 1184788416
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,911 of the $9,696 with a category attached, or 61.0%. Edwards Lifesciences accounts for 79.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,971 and has fallen 55.5% since, to $1,323 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 85 payments — averaging $114.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$8K
- Medtronic$1K
- Abbott$623
- Cardinal Health 200 LLC$124
- Boston Scientific$102
- Siemens Medical Solutions USA, Inc.$71
- plus $47 from 1 others
Across 5 payments — averaging $9170.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$46K
What the payments were for
- Travel & lodging$5,91161%
- Food & beverage$3,78439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 55 | $7,704 |
| Medtronic(2 entities) | 15 | $1,025 |
| Abbott | 9 | $623 |
| Cardinal Health 200 LLC | 1 | $124 |
| Boston Scientific | 1 | $102 |
| Siemens Medical Solutions USA, Inc. | 2 | $71 |
| Philips North America LLC | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,696 in reported general payments places this provider in the 50th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 72 | $54,443 |
| EntrestoSacubitril/Valsartan | 55 | $53,860 |
| FarxigaDapagliflozin Propanediol | 46 | $29,374 |
| EliquisApixaban | 30 | $28,688 |
| Ranolazine ErRanolazine | 21 | $1,531 |
| Ezetimibe | 71 | $1,457 |
| Metoprolol Succinate | 122 | $1,431 |
| Rosuvastatin Calcium | 81 | $954 |
| Atorvastatin Calcium | 79 | $736 |
| ClopidogrelClopidogrel Bisulfate | 53 | $706 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 46 | $386 |
| Nitroglycerin | 24 | $382 |
| Losartan Potassium | 38 | $347 |
| Carvedilol | 37 | $318 |
| Lisinopril | 22 | $295 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Dallas
- Robert StolerDallas$587K
- Byung ParkDallas$236K
- James ChoiDallas$211K
- Tony DasDallas$187K
- Kenneth JohnsonDallas$113K
- Srinivas YallapragadaDallas$99K
- Wally OmarDallas$84K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.